MindBio Prepares for Phase 3 Clinical Trials
 |
|||||||||
 |
 |
||||||||
Upgrades Clinical Software & Data Analytics Capabilities
Vancouver, British Columbia – TheNewswire – Oct 14, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a pioneering clinical-stage biopharmaceutical company dedicated to developing novel and effective mental health treatments, is pleased to announce in preparation for Phase 3 clinical trials, the Companhy has upgraded its mobile application technology and backend software for use in clinical trials data collection and analysis.
The Company is completing the development of a sophisticated clinical application software to collect, store and analyse patient biometric and activity data from wearables such as Fitbits and Garmin watches and core clinical trial data including pharmacokinetic and pharmacodynamic data, EEG, ECG, DNA and other data from bloodwork and psychometric testing. The data collection initiatives over the past 5 years and into the future and the advancement of the Company’s software and machine learning capabilities are a core part of MindBio’s intellectual property moat around its lead candidate MB22001, a microdose form of lysergic acid diethylamide uniquely formulated for safe, take home use by patients. The data informs effective patient dosing and treatment and reinforces MindBio’s position as the lead commercial opportunity for take-home psychedelics.
The new software has been acquired from a clinical software vendor to enable the Company to move away from an academic clinical trial environment into full scale Phase 3 readiness and a commercialisation pathway for MindBio’s lead candidate drug MB22001. The software vendor will be paid CAD$450,000 by issuing 50,000,000 common shares in the Company at the 20 day VWAP of CAD$0.009 per share. Further, the software vendor will be issued 35,000,000 share purchase warrants, with an exercise price equal to the previous day share price close (and a minimum exercise price of CAD$0.05) with the exercise price calculated on the date of completion of integration of the software. It is expected the integration will take a few months. The deal struck with the clinical software vendor provides a significant potential capital raising opportunity upon exercise of the warrants for the Company on successful integration of the software and aligns the vendor with the success of MindBio.
For the past 5 years, MindBio has operated its trials by engaging over 20 scientists in a multi-disciplinary collaboration effort with the departments of Engineering, Psychiatry, Pharmacology and Medicine at a tier 1 University in Australasia. The Company will soon move its Phase 3 trials to a large scale global commercial provider of clinical trials.
“The updating of our data collection and analysis capabilities in preparation for Phase 3 clinical trials is another small step towards our commercialisation objective for our lead candidate drug MB22001” said Justin Hanka, Chief Executive Officer of MindBio Therapeutics. “We believe that MB22001 is the most advanced take home use case of a psychedelic medicine in clinical development and we look forward to progressing this important new treatment for depression”.
The Company is currently in the very final completion stages of Phase 2B clinical trials with the last doses being administered to patients. A top line data readout of these landmark Phase 2B clinical trials is expected this quarter.
MindBio invites stakeholders, partners, and the global community to join in supporting its vision for a brighter future in mental health. For more information about MindBio Therapeutics, MB22001, or opportunities for collaboration, please visit www.mindbiotherapeutics.com.
About MindBio Therapeutics
MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, focused on developing novel psychedelic-based medicines for mental health disorders. With a commitment to scientific rigor and patient accessibility, MindBio is pioneering the use of regulated, take-home use of psychedelic medicines in clinical trials to provide safe, effective, and scalable treatments for conditions such as depression, anxiety, and other psychological challenges. The company’s mission is to improve global mental health outcomes through innovative, evidence-based treatment that is accessible and affordable.
For further information, please contact:
Justin Hanka, Chief Executive Officer
61 433140886
Media Inquiries
Kristina Spionjak
Cautionary Note Concerning Forward-Looking Statements:
The press release contains “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “budget,” “believe,” “project,” “estimate,” “expect,” “scheduled,” “forecast,” “strategy,” “future,” “likely,” “may,” “to be,” “could,” “would,” “should,” “will” and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
Additionally, there are known and unknown risk factors that could cause the Company’s actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.
The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2025 TheNewswire – All rights reserved.
